WuXi Biologics reported a 16.7% increase in revenue to RMB 21.8 billion and a 45.3% rise in IFRS net profit to RMB 5.7 billion for 2025, fueled by strong demand for complex biologics like bispecific antibodies and ADCs. The company expanded its project portfolio to 945 integrated programs and enhanced manufacturing capacity globally, including new facilities in the US, Singapore, and Qatar. Gross profit margin improved by 500 basis points to 46.0%, supported by operational efficiencies and digitalization. WuXi Biologics plans to continue expanding its global CRDMO network and invest in advanced technologies to sustain growth.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Trupanion, a pet insurance provider, operates in the growing pet care market with subscription plans for cats and dogs. Despite a recent 2.68% dip, the stock has gained 4.13% over 30 days, indicating positive momentum and a potential buying opportuni...
Cass Information Systems reported strong first-quarter earnings of $0.66 per share, beating estimates, and achieved record annual net income of $35.1 million. The company is improving operational efficiency through automation and workforce reductions...
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
Citigroup lowered its price target for Ericsson to SEK 105 from SEK 110 and kept a Neutral rating after the company's Q2 2026 results missed revenue and earnings estimates. Ericsson's shares dropped over 13% due to rising component costs, especially ...
